JP2022513215A - Ｃ－ｍｅｔ阻害剤としての有機リン置換化合物およびその治療用途 - Google Patents

Ｃ－ｍｅｔ阻害剤としての有機リン置換化合物およびその治療用途 Download PDF

Info

Publication number
JP2022513215A
JP2022513215A JP2021533641A JP2021533641A JP2022513215A JP 2022513215 A JP2022513215 A JP 2022513215A JP 2021533641 A JP2021533641 A JP 2021533641A JP 2021533641 A JP2021533641 A JP 2021533641A JP 2022513215 A JP2022513215 A JP 2022513215A
Authority
JP
Japan
Prior art keywords
alkyl
independently
pharmaceutically acceptable
hydrogen
solvate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021533641A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022513215A5 (https=
Inventor
ジャン，ドン
ペン，ジロン
ニコラス グレコ，マイケル
ジョン コスタンゾ，マイケル
アラン グリーン，マイケル
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Beta Pharma Inc
Original Assignee
Beta Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beta Pharma Inc filed Critical Beta Pharma Inc
Publication of JP2022513215A publication Critical patent/JP2022513215A/ja
Publication of JP2022513215A5 publication Critical patent/JP2022513215A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/50—Organo-phosphines
    • C07F9/5004—Acyclic saturated phosphines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/30—Phosphinic acids [R2P(=O)(OH)]; Thiophosphinic acids ; [R2P(=X1)(X2H) (X1, X2 are each independently O, S or Se)]
    • C07F9/32—Esters thereof
    • C07F9/3205—Esters thereof the acid moiety containing a substituent or a structure which is considered as characteristic
    • C07F9/3211—Esters of acyclic saturated acids which can have further substituents on alkyl

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2021533641A 2018-12-14 2019-12-14 Ｃ－ｍｅｔ阻害剤としての有機リン置換化合物およびその治療用途 Pending JP2022513215A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862779960P 2018-12-14 2018-12-14
US62/779,960 2018-12-14
PCT/US2019/066414 WO2020124060A1 (en) 2018-12-14 2019-12-14 Organophosphorus-substituted compounds as c-met inhibitors and therapeutic uses thereof

Publications (2)

Publication Number Publication Date
JP2022513215A true JP2022513215A (ja) 2022-02-07
JP2022513215A5 JP2022513215A5 (https=) 2022-11-24

Family

ID=71077551

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021533641A Pending JP2022513215A (ja) 2018-12-14 2019-12-14 Ｃ－ｍｅｔ阻害剤としての有機リン置換化合物およびその治療用途

Country Status (15)

Country Link
US (1) US12258365B2 (https=)
EP (1) EP3893872B1 (https=)
JP (1) JP2022513215A (https=)
KR (1) KR20210111779A (https=)
CN (1) CN113412112B (https=)
AU (1) AU2019395282A1 (https=)
BR (1) BR112021011547A2 (https=)
CA (1) CA3122575A1 (https=)
EA (1) EA202191541A1 (https=)
IL (1) IL283589A (https=)
MX (1) MX2021006982A (https=)
SG (1) SG11202105872RA (https=)
TW (1) TW202039500A (https=)
WO (1) WO2020124060A1 (https=)
ZA (1) ZA202104000B (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116969955B (zh) * 2023-09-25 2023-12-19 中国药科大学 一种[1,2,4]三唑[4,3-b]哒嗪类化合物及其制法与应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009536636A (ja) * 2006-05-11 2009-10-15 ファイザー・プロダクツ・インク 抗癌剤として有用なトリアゾロピラジン誘導体

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20170103T1 (hr) 2005-12-21 2017-03-24 Janssen Pharmaceutica N.V. Triazolopiridazini kao modulatori tirozin kinaze
US20110039856A1 (en) * 2007-11-29 2011-02-17 Pfizer Inc. Polymorphs of a c-met/hgfr inhibitor
UY32049A (es) 2008-08-14 2010-03-26 Takeda Pharmaceutical Inhibidores de cmet
EA030141B1 (ru) 2009-12-31 2018-06-29 Хатчисон Медифарма Лимитед Определенные триазолопиридины и триазолопиразины, их композиции и способы их применения
ES2598530T3 (es) 2010-07-14 2017-01-27 Betta Pharmaceuticals Co., Ltd. Nuevos derivados heterocíclicos condensados útiles como inhibidores de la tirosina quinasa c-Met
TWI520962B (zh) * 2012-06-29 2016-02-11 As the c-Met tyrosine kinase inhibitors novel fused pyridine derivatives
CN103122000B (zh) * 2012-09-03 2013-12-25 中美冠科生物技术（太仓）有限公司 用作抗肿瘤药物的高选择性的c-Met激酶抑制剂
ES2877799T3 (es) * 2015-12-31 2021-11-17 Shanghai Pharmaceuticals Holding Co Ltd Sal de derivado de quinolina, formas polimórficas de la misma, métodos de preparación de la misma, composición y aplicaciones

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009536636A (ja) * 2006-05-11 2009-10-15 ファイザー・プロダクツ・インク 抗癌剤として有用なトリアゾロピラジン誘導体

Also Published As

Publication number Publication date
CN113412112A (zh) 2021-09-17
EP3893872B1 (en) 2024-07-17
KR20210111779A (ko) 2021-09-13
CN113412112B (zh) 2024-06-11
EA202191541A1 (ru) 2022-01-21
TW202039500A (zh) 2020-11-01
WO2020124060A1 (en) 2020-06-18
SG11202105872RA (en) 2021-07-29
EP3893872A4 (en) 2022-08-10
EP3893872A1 (en) 2021-10-20
US12258365B2 (en) 2025-03-25
MX2021006982A (es) 2021-09-10
AU2019395282A1 (en) 2021-07-08
ZA202104000B (en) 2022-08-31
BR112021011547A2 (pt) 2021-08-31
CA3122575A1 (en) 2020-06-18
US20220064194A1 (en) 2022-03-03
IL283589A (en) 2021-07-29

Similar Documents

Publication Publication Date Title
JP7073554B2 (ja) 肺がん、膵臓がん、または大腸がんを治療するためのＫＲＡＳ Ｇ１２Ｃ阻害剤としての、ベンズイソチアゾール、イソチアゾロ［３，４－ｂ］ピリジン、キナゾリン、フタラジン、ピリド［２，３－ｄ］ピリダジンおよびピリド［２，３－ｄ］ピリミジン誘導体
TWI680126B (zh) Cot 調節劑及其使用方法
TWI725266B (zh) Fgfr4抑制劑、其製備方法與藥學上的應用
JP5414794B2 (ja) Ｃ−ｍｅｔの阻害剤として有用なアミドフェノキシインダゾール
WO2018045957A1 (zh) 一种cdk4/6抑制剂及其制备方法和应用
WO2014160873A1 (en) Benzimidazolone derivatives as bromodomain inhibitors
JP2016517412A (ja) Ｆａｓｎを阻害するための新規化合物および組成物
JP2011510058A (ja) Ｃ−ｍｅｔの阻害剤として活性な縮合ピリジン
KR20180022982A (ko) Cot 조정제 및 그의 사용 방법
BRPI0716224A2 (pt) Compostos inibidores de raf e métodos de uso dos mesmos.
WO2012019427A1 (zh) 酞嗪酮类衍生物、其制备方法及其在医药上的应用
AU2015369712A1 (en) Mutant IDH1 inhibitors useful for treating cancer
CN113045559A (zh) 一种二芳基脲类PI3Kα/mTOR双靶点抑制剂及其药物组合物和应用
AU2020404978A1 (en) CD206 modulators their use and methods for preparation
CN115677730B (zh) 8-氧-3-氮杂二环[3.2.1]辛烷类化合物或其盐及其制备方法和用途
CN115340559A (zh) Shp2磷酸酶杂环类抑制剂的制备及其应用
CN110691775B (zh) 一种具有fgfr4抑制活性的醛基吡啶衍生物、其制备方法和应用
JP2022513215A (ja) Ｃ－ｍｅｔ阻害剤としての有機リン置換化合物およびその治療用途
JP2026507587A (ja) ジヒドロベンズイミダゾロンコアを有するｄｄｒ１およびｄｄｒ２阻害剤
WO2024245326A1 (zh) 含氮官能团取代的哒嗪并吡啶酮衍生物及其用途
WO2022166468A1 (zh) Bruton's酪氨酸激酶抑制剂及其应用
CN115960109A (zh) 稠环类shp2磷酸酶抑制剂的制备及其应用
TW201305171A (zh) 酞嗪酮類衍生物、其製備方法及其在醫藥上的應用
HK40029610B (zh) 一种哒嗪类衍生物抑制剂、其制备方法和应用

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221115

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20221115

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20231109

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20231121

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20240618